Results 21 to 30 of about 42,088 (274)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis

Archives of Medical Science, 2021
Introduction The aim of the study was to study a nanoliposomal anti-PCSK9 vaccine as a novel approach for cholesterol lowering via PCSK9 inhibition. Material and methods An immunogenic peptide construct termed immunogenic fused PCSK9-tetanus (IFPT) was ...
Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Mohammad Afshar, Maciej Banach, Amirhossein Sahebkar   +4 more
doaj   +1 more source

Pro-inflammatory Vascular Stress in Spontaneously Hypertensive Rats Associated With High Physical Activity Cannot Be Attenuated by Aldosterone Blockade

Frontiers in Cardiovascular Medicine, 2021
The effect of high physical activity, performed as voluntary running wheel exercise, on inflammation and vascular adaptation may differ between normotensive and spontaneously hypertensive rats (SHRs). We investigated the effects of running wheel activity
Rolf Schreckenberg, Annemarie Wolf, Christian Troidl, Sakine Simsekyilmaz, Klaus-Dieter Schlüter   +4 more
doaj   +1 more source

Protein structural insights into a rare PCSK9 gain-of-function variant (R496W) causing familial hypercholesterolemia in a Saudi family: whole exome sequencing and computational analysis

Frontiers in Physiology, 2023
Familial hypercholesterolemia (FH) is a globally underdiagnosed genetic condition associated with premature cardiovascular death. The genetic etiology data on Arab FH patients is scarce.
Noor Ahmad Shaik, Noor Ahmad Shaik, Najla Al-Shehri, Mohammad Athar, Mohammad Athar, Ahmed Awan, Mariam Khalili, Hadiah Bassam Al Mahadi, Gehan Hejazy, Omar I. Saadah, Sameer Eida Al-Harthi, Ramu Elango, Ramu Elango, Babajan Banaganapalli, Babajan Banaganapalli, Eman Alefishat, Eman Alefishat, Eman Alefishat, Zuhier Awan   +18 more
doaj   +1 more source

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

Journal of Lipid Research, 2014
Secreted PCSK9 binds to cell surface LDL receptor (LDLR) and directs the receptor for lysosomal degradation. PCSK9 is potent at inducing LDLR degradation in cultured liver-derived cells, but it is considerably less active in immortalized fibroblasts.
My-Anh Nguyen, Tanja Kosenko, Thomas A. Lagace   +2 more
doaj   +1 more source

Past, Present, and Future of Familial Hypercholesterolemia Management

Methodist DeBakey Cardiovascular Journal, 2021
Familial hypercholesterolemia (FH) is a monogenic form of severe hypercholesterolemia that, if left untreated, is associated with early onset of atherosclerosis.
Viviane Z. Rocha, Raul D. Santos
doaj   +1 more source

Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]

, 2017
No abstract ...
Packard, Chris J.
core   +1 more source

Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G

JCI Insight, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
Alexander Merleev, Antonio Ji-Xu, Atrin Toussi, Lam C. Tsoi, Stephanie T. Le, Guillaume Luxardi, Xianying Xing, Rachael Wasikowski, William Liakos, Marie-Charlotte Brüggen, James T. Elder, Iannis E. Adamopoulos, Yoshihiro Izumiya, Annie R. Leal, Qinyuan Li, Nikolay Y. Kuzminykh, Amanda Kirane, Alina I. Marusina, Johann E. Gudjonsson, Emanual Maverakis   +19 more
doaj   +1 more source

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]

, 2016
BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven, Ganz, Peter, Grunfeld, Carl, Hsue, Priscilla Y, Hur, Sophia, Kohli, Payal, Ma, Yifei, Scherzer, Rebecca, Scott, Rob, Wasserman, Scott, Weigel, Bernard   +10 more
core   +1 more source

Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line [PDF]

, 2015
The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor (TNF-\u3b1).
Corsini, Alberto, Cristofani, Riccardo, Ferri, Nicola, Liu, Jingwen, Macchi, Chiara, Magni, Paolo, Ricci, Chiara, Ruscica, Massimiliano   +7 more
core   +2 more sources

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]

Journal of Lipid Research, 2015
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact ...
Krista M. Schroeder, Thomas P. Beyer, Ryan J. Hansen, Bomie Han, Richard T. Pickard, Victor J. Wroblewski, Mark C. Kowala, Patrick I. Eacho   +7 more
doaj   +1 more source